<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142861">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820884</url>
  </required_header>
  <id_info>
    <org_study_id>2012-GYN/EC-02</org_study_id>
    <nct_id>NCT01820884</nct_id>
  </id_info>
  <brief_title>The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma</brief_title>
  <acronym>EC-02</acronym>
  <official_title>The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ding Ma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial is studying the efficacy and safety of the hysterectomy alone compared
      with hysterectomy and bilateral salpingo-oophorectomy (BSO) for patients with Stage IA
      endometrial carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3-year DFS</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical gynecologic endocrine function</measure>
    <time_frame>1-year period</time_frame>
    <safety_issue>No</safety_issue>
    <description>To observe the level of female hormone，i.e., estrogen, FSH, LH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3-year period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3-year OS</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Total Hysterectomy (TH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TH and bilateral salpingo-oophorectomy (TH/BSO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TH</intervention_name>
    <description>Total hysterectomy</description>
    <arm_group_label>Total Hysterectomy (TH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TH/BSO</intervention_name>
    <description>Total hysterectomy and bilateral salpingo-oophorectomy</description>
    <arm_group_label>TH and bilateral salpingo-oophorectomy (TH/BSO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BPLND</intervention_name>
    <description>bilateral pelvic and para-aortic lymph node dissection</description>
    <arm_group_label>Total Hysterectomy (TH)</arm_group_label>
    <arm_group_label>TH and bilateral salpingo-oophorectomy (TH/BSO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FIGO stage: ⅠA, endometrial carcinoma;

          -  Female, Chinese women;

          -  premenopausal women；

          -  ≤ 50 years old;

          -  Pathological diagnosis by curettage/hysteroscopy : G1

          -  No prior treatment;

          -  Provide written informed consent.

        Exclusion Criteria:

          -  The suspicious metastasis of ovarian;

          -  Family history of ovarian cancer;

          -  Suffering from other malignancies;

          -  Concurrently participating in other clinical trials;

          -  Unable or unwilling to sign informed consents;

          -  Unable or unwilling to abide by protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beihua Kong, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danhui Weng, MD, PhD</last_name>
    <phone>+862783662681</phone>
    <email>weng.dh@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danhui Weng, MD</last_name>
      <phone>+862783662681</phone>
      <email>weng.dh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Changyu Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital，Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingsheng Yang, MD, Ph D</last_name>
      <phone>13791123129</phone>
      <email>xingshengyang@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Xingsheng Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuyan Mao, MD</last_name>
      <phone>13989816955</phone>
      <email>maoyy3@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yuyan Mao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of the department of Obstetrics and Gynecology, Tongji Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
